



MONEY MANAGEMENT
**FUND MANAGER
OF THE YEAR 2020**

AUSTRALIA'S FIRST INDEPENDENT AND WHOLE OF MARKET AWARDS

WINNER
Australian Small/Mid Cap Equities

Fairview Equity Partners Emerging Companies Fund

31 December 2023



Monthly Report

About the Fund

The Fund invests in an actively managed portfolio of mainly small cap equities listed, or expected to be listed, on the Australian share market.

Investment Objective

The Fund aims to earn a return (after fees) which exceeds the benchmark over rolling five-year periods.

Benchmark

S&P/ASX Small Ordinaries Total Return Index ("Benchmark")

Inception Date

8 October 2008

mFund Code

FEP01

APIR Code

ANT0002AU

Minimum Initial Investment

\$20,000

Management Fee

1.20% p.a. of the Fund's Net Asset Value.

Performance Fee

20.5% of the Funds quarterly return (after deducting the management fee) in excess of the benchmark's quarterly return after recouping any prior periods' underperformance in dollar terms multiplied by the Fund's average Net Asset Value over the quarter.

Distribution Frequency

Annually calculated on 30 June. However, there may be periods in which no distributions are made or the Fund may make additional distributions.

Buy/Sell Spread

+0.30% / -0.30%

Number of Stocks

55

Contacts

www.mlc.com.au
fairviewequity.com.au
Email: client.services@mlc.com.au
Client Services: 1300 738 355


Net Performance

	1 month	3 months	1 year	3 years	5 years	10 years	Since inception ¹
	%	%	%	% p.a.	% p.a.	% p.a.	% p.a.
Fund Return²	5.47	7.35	12.83	4.29	12.34	8.68	10.84
Benchmark³	7.23	8.52	7.82	0.95	6.40	6.01	5.03
Excess Return	-1.76	-1.17	5.01	3.34	5.94	2.67	5.81

¹Fund inception date: 8 October 2008. ²Net returns are calculated after deducting management fees and are pre-tax.

³Benchmark: S&P/ASX Small Ordinaries Total Return Index. Past performance is not a reliable indicator of future performance. The value of an investment may rise or fall with the changes in the market.

Growth of \$100,000 since inception



MONEY MANAGEMENT
**FUND MANAGER
OF THE YEAR 2020**

AUSTRALIA'S FIRST INDEPENDENT AND WHOLE OF MARKET AWARDS

WINNER
Australian Small/Mid Cap Equities

Monthly Commentary – December 2023

The Fairview Emerging Companies Fund delivered a 5.47% return in December, to be 12.83% higher over 2023. The Small Ordinaries Total Return Index surged 7.23% over the month, completing a strong end to finish the year nicely in the positive, up 7.82%.

While the fund struggled to keep pace in December, over the year, it delivered a return that was 5.01% higher than the benchmark.

Jerome dressed as Santa

At the start of the month Federal Reserve Chairman Jerome Powell lit up equity markets when market pundits latched onto a subtle change in his tone from describing Fed Reserve policy as “restrictive” in a speech several weeks earlier, to now describing their policy as “well into restrictive territory”. This was interpreted as rate cuts were close and a hard economic landing was likely to be averted (according to Bloomberg a third of US forecasters still anticipate a recession). A year-end rally in interest rate sensitive stocks occurred, with strength seen in such underweight sectors as Consumer Discretionary and REITs, as well as equity market beta names such as the listed fund managers. As observed in recent years, for a bottom-up stock picking fund, it can be these sudden capital rotations which can cause short term slippage vs the benchmark.

Santa delivered the strongest December in 30 years

While December is a historically strong month for the Australian small cap sector, 2023 saw its second-best December monthly return since inception and the best since 1993 when the market gained 11%.

Small caps pipped the big caps over Q4

The Australian small cap sector kept pace with the ASX100 during December but underperformed its bigger peer by 3% over the year. This followed 2022 when the ASX100 outperformed the small caps by 17%. Pleasingly, the small cap sector showed glimpses of a much-anticipated performance recovery in the final quarter of 2023.

The same could not be said for the ASX Small Resources, which fell behind the Industrials by a further 5% to finish the year 13% below. While a headwind for the fund, unitholders still benefitted over the year from stock selection. Lithium was a key index detractor across the 12-month period, with the spodumene price slumping ~80% and marginal production starting to withdraw from the market (ie Core Lithium). Overall, the fund’s lithium exposure generated solid outperformance over 2023 due to a preference for asset quality which attracted M&A.

M&A bonanza pre-Christmas

The 18th day of the month quickly became known as M&A Monday, with the announcement of several deals contributing to a few of the month’s best small cap share price performers. Link Group (LNK) and Adelaide Brighton (ABC) both caught bids after cleansing the market with positive news – LNK announced positive steps towards extending a large client contract, while ABC provided positive earnings guidance. Having seen its share price slump 2/3rds over the last two years, dentist business Pacific Smiles (PSQ) received a bid from a Sydney-based private equity firm. On the same day Ridley Corporation (RIC) acquired a business and top-100 company Stockland Group (SGP) spent \$1bn buying an asset from Lendlease (LLC). All this activity followed the back-door listing announcement of Chemist Warehouse into Sigma Healthcare (SIG). The fund saw no material benefit from M&A in December, with just a small bump in the takeover price for lithium developer, Azure Minerals (AZS). Across the small cap market, the LNK & ABC transactions accounted for ~20% of the

year's total M&A activity. While according to FactSet, completed ASX small cap M&A in 2023 was down 40% compared to the prior year.

A biotech success

On the flipside Australian Clinical Labs' (ACL) attempt to merge with Healius (HLS) was unsurprisingly thwarted by the competition regulator, the ACCC. Staying within the healthcare sector, the best small cap share price performer across the month and year, was neurological drug biotech company, Neuren Pharmaceutical (NEU). The company's first US commercial sales of its trofinetide drug occurred in April with exemplary execution from its US partner, while NEU ended the year with positive trial data for its second drug application. Thankfully, unitholders benefitted from the company's stellar 12-month return which saw its share price grow threefold.

In contrast, the market saw disappointing trading updates from Costa Group (under takeover) and PEXA Group. At the nano cap end of the market both Kathmandu (a milder winter) and Motorcycle Holdings (farm vehicles) pointed to some pockets of weakness. We now look forward to further company updates, hopefully positive, in January as a lead into the February reporting season.

Consumer resiliency a highlight

As we enter 2024 and contemplate the path for interest rates (money markets are pricing the Fed Reserve to start cutting rates in March 2024 with a total of six rate cuts totalling 1.5% anticipated for the year ahead), the November US presidential election, the evolution of artificial intelligence, China's economic path, the prospect for more global conflict and continued nationalisation amongst many other variables, it's worth reflecting on 2023 for a moment. A surprise for many was the Australian consumer's resiliency in the face of rising rates and inflationary cost pressures with no mortgage cliff yet to emerge. While the domestic household savings ratio (1%) is now tracking well below the 4-year pre-Covid average (6%), rising wages have also helped, but net overseas migration in the last two years has also been unprecedented. Australia has added close to 1m people, which is roughly the equivalent of four years migration compressed into two (clearly encouraged to counter a lack of migration during the Covid years of 2020 and 2021).

Investment Team



Michael Glenane

Portfolio Manager

BE, MBA

31+ years investment management experience



Tim Hall

Portfolio Manager

BComm

25+ years investment management experience



Leo Barry

Portfolio Manager

BSA, MBA

16+ years investment management experience

This report is issued by MLC Investments Limited ABN 30 002 641 661, AFSL 230705 ('MLCI'), the responsible entity of, and the issuer of units in, the Fairview Equity Partners Emerging Companies Fund, ARSN 133 197 501 (the 'Fund'). MLCI has appointed Fairview Equity Partners Pty Ltd ('Fairview'), ABN 45 131 426 938, AFSL 329052, a specialist Australian small company equities manager, as investment manager of the Fund. An investor should consider the current Product Disclosure Statement ('PDS') for the Fund in deciding whether to acquire, or continue to hold, units in the Fund and consider whether units in the Fund are an appropriate investment for the investor, and the risks of any investment. The PDS is available from mlcam.com.au or by calling the Client Services Team on 1300 738 355. The information in this report may constitute general advice. This report does not take account of an investor's particular objectives, financial situation or needs. Investors should therefore, before acting on information in this report, consider its appropriateness, having regard to the investor's own particular objectives, financial situation or needs. We believe that the information contained in this report is correct and that any estimates, opinions, conclusions or recommendations are reasonably held or made at the time of compilation. However, no warranty is made as to their accuracy or reliability. The information in this communication is subject to change without notice. All statements as to future matters are not guaranteed to be accurate and any statement as to past performance is not a reliable indication of future performance. MLCI is part of the Insignia Group of companies (comprising Insignia Financial Limited ABN 49 100 103 722 and its related bodies corporate) ('Insignia Financial Group'). The capital value, payment of income and performance of the Fund are not guaranteed. An investment in the Fund is subject to investment risk, including possible delays in repayment and loss of income and principal invested.

References to Money Management's Fund Manager of the Year awards and use of logo: © 2020 FE Money Management. all rights reserved. The information, data, analyses, and opinions contained herein (1) include the proprietary information of FE Money Management (2) may not be copied or redistributed (3) do not constitute investment advice offered by FE Money Management (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a security (5) are not warranted to be correct, complete, or accurate. FE Money Management shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, this information, data, analyses, or opinions or their use. FE Money Management does not guarantee that a fund will perform in line with its Fund Manager of the Year award as it reflects past performance only. Likewise, the Fund Manager of the Year award should not be any sort of guarantee or assessment of the creditworthiness of a fund or of its underlying securities and should not be used as the sole basis for making any investment decision.